A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms APOSTLE
- 07 Sep 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 07 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 May 2019.
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.